BIO ON overview

PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab) PR Newswire LONDON, Feb. 8, 2023 London based deal experts are the exclusive advisors for this and the ongoing partnering efforts for WM-A1-3389 LONDON , Feb. 8, 2023 /PRNewswire/ -- PharmaVentures is pleased to announce that it acted as exclusive advisor for Wellmarker Bio Co., Ltd (WMBIO) on its collaboration with MSD (Merck & Co., Inc.,...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) on behalf of Instil Bio stockholders. Our investigation concerns whether Instil Bio has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or misleading...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sesen Bio, Inc. (“Sesen” or the “Company”) (NASDAQ: SESN) on behalf of Sesen stockholders. Our investigation concerns whether Sesen has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Sesen is a late-stage clinical company advancing targeted fusion protein therapeutics for the...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSEAM: ANVS) on behalf of Annovis stockholders. Our investigation concerns whether Annovis has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Annovis is a clinical-drug company that develops drugs for the treatment of neurodegenerative...

Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs PR Newswire MUMBAI, India, Aug. 27, 2020 - Integrated program encompasses formulation development, drug substances and drug product manufacturing - Project involves three Piramal Pharma Solutions (PPS) sites in India - New, specialized technologies have been added in a dedicated area MUMBAI, India , Aug. 27, 2020 /PRNewswire/ -- Piramal Pharma Solutions, a leading...

Kaskela Law LLC has commenced an investigation of IVERIC bio, Inc. (“IVERIC” or the “Company”) (Nasdaq: ISEE), formerly known as Ophthotech Corp., on behalf of the Company’s stockholders. IVERIC stockholders who purchased shares of the Company’s stock before December 12, 2016 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 – 1740 to discuss this investigation and their legal rights and options. Additional information about this investigation may...

The company's main economic and financial data is as follows: Revenues of 51 million Euro at 31 December 2018 compared to 10 million Euro in 2018; EBITDA of 43 million Euro at 31 December 2018 compared to 7 million Euro at 31 December 2017; EBIT of 40 million Euro at 31 December 2018 compared to 6 million Euro at 31 December 2017; Net income of 33.5 million Euro at 31 December 2018 compared to 5 million Euro at 31 December 2017; Negative net financial position (debt) of 20 million Euro compared...

Consolidated revenues of 51 million Euro at 31 December 2018 compared to 11 million Euro at 31 December 2017; EBITDA of 42 million Euro at 31 December 2018 compared to 7 million Euro at 31 December 2017; EBIT of 40 million Euro at 31 December 2018 compared to 6 million Euro at 31 December 2017; Net income of 12 million Euro at 31 December 2018 compared to 5 million Euro at 31 December 2017; Negative net financial position (debt) of 23 million Euro compared to 24 million Euro (assets) in 2017 and...